Security key
59102M104
- Security type / class
- Equity / COM
- Total 13F shares
- 11,662,818
- Total 13F value
- $25,306,458
- Share change
- -548,323
- SEC-reported price per share
- $2.17
- Number of holders
- 65
- Value change
- -$3,651,260
- Number of buys
- 40
- Number of sells
- 20
Report period
Q3 2024
Institutions
65
Top holders
10
MGX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Metagenomi Therapeutics, Inc. SEC filings
Metagenomi Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59102M104
Recent filing periods:
Ownership snapshot
Top reported holders of MGX - Metagenomi Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAYER HEALTHCARE LLC
Disclosed value leader
BAYER HEALTHCARE LLC
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5
13F
Highest disclosed value: $11,666,871
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
BAYER HEALTHCARE LLC has the largest disclosed position value at $11.67M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAYER HEALTHCARE LLC's linked filing trail.
Disclosed position value
Top 5
BAYER HEALTHCARE LLC
$11.67M
Novo Holdings A/S
$7.34M
Sebastian Bernales
$6.62M
RA CAPITAL MANAGEMENT, L.P.
$6.03M
FARALLON CAPITAL MANAGEMENT, L.L.C.
$5.48M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAYER HEALTHCARE LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$11,666,871
4,050,997 shares
|
— | 13 Feb 2024 |
| Novo Holdings A/S |
13F
3/4/5
Company · 10%+ Owner
|
—
class O/S missing
|
$7,344,000
1,800,000 shares
|
— | 30 Jun 2024 |
| Sebastian Bernales |
3/4/5
Director
|
—
mixed-class rows
|
$6,620,950
3,147,422 shares
mixed-class rows
|
— | 01 Apr 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
class O/S missing
|
$6,029,216
1,477,749 shares
|
— | 30 Jun 2024 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
—
class O/S missing
|
$5,480,260
1,343,201 shares
|
— | 30 Jun 2024 |
| PFM Health Sciences, LP |
13F
Company
|
—
class O/S missing
|
$5,169,368
1,267,002 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
65
Shares
11,662,818
Rows available
65
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q1 2026 Across Filers
Q1 2026 holders
47
Q3 2024 holders
65
Holder diff
18
| Investor | Q1 2026 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend